immune checkpoint

Information about the genomic and immunological characteristics of blood cancers is helping scientists discover and develop new immunotherapies.

Cancer immunotherapy targets the tumor microenvironment, blocking the molecular pathways that tumors exploit to prevent immune cell activity.

A robust, automated western blot system accelerates immunotherapy development.

The binding of histamine with one of its receptors within the tumor environment makes cancer cells more resistant to immunotherapy, according to a new study. Blocking that binding could improve responses to treatment.

Researchers use Perturb-CITE-seq to perform powerful multiomic pooled CRISPR screens.

Researchers describe ways to study how cancer cells evade therapies that harness the immune system.

Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.

Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.

The immunologists, honored with the 2018 award in Physiology or Medicine, pioneered immunotherapy, which harnesses the body’s immune system to fight cancer.

The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.

Genetic analyses uncover cellular hallmarks of bladder cancer tumors that don’t respond, but interfering with one of those characteristics in a mouse model causes tumors to shrink.  

Using a large CRISPR-based screen, researchers find possible genetic culprits for patients not having success with immune checkpoint inhibitors.  

A drug that blocks an immune checkpoint protein effectively treats tumors in patients with deficient DNA repair genes.